
Sign up to save your podcasts
Or
Despite great hopes for Artificial Intelligence (AI) in biotech and pharma—with investments exceeding $50 billion over the past ten years—the question of when the technology will reach maturity remains difficult to answer. How can biotech and pharma leaders navigate this complex gray area, where hype around the technology obscures the outlook and few concrete milestones provide clear signposts for decision-making?
In this episode of the BioRevolution podcast, Louise von Stechow and Andreas Horchler speak with their guest, idalab founder Paul von Bünau, about the potential of AI in biotech. They explore how leaders can adapt internal processes, support their teams in facing the challenges AI brings, and examine whether AI has the potential to make us better leaders.
Find Dr. Paul von Bünau here: https://www.linkedin.com/in/paulvonbuenau/
Disclaimer:
Learn more about the future of biotech in our podcasts and keynotes. Contact us here:
Image: Matteo Vistocco via Unsplash
References:
Despite great hopes for Artificial Intelligence (AI) in biotech and pharma—with investments exceeding $50 billion over the past ten years—the question of when the technology will reach maturity remains difficult to answer. How can biotech and pharma leaders navigate this complex gray area, where hype around the technology obscures the outlook and few concrete milestones provide clear signposts for decision-making?
In this episode of the BioRevolution podcast, Louise von Stechow and Andreas Horchler speak with their guest, idalab founder Paul von Bünau, about the potential of AI in biotech. They explore how leaders can adapt internal processes, support their teams in facing the challenges AI brings, and examine whether AI has the potential to make us better leaders.
Find Dr. Paul von Bünau here: https://www.linkedin.com/in/paulvonbuenau/
Disclaimer:
Learn more about the future of biotech in our podcasts and keynotes. Contact us here:
Image: Matteo Vistocco via Unsplash
References: